Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Lung cancer is frequently caused by activating mutations in the epidermal growth factor receptor (EGFR). Allosteric EGFR inhibitors offer promise as the next generation of therapeutics, as they are unaffected by common ATP-site resistance mutations and synergize with the drug osimertinib. Here, we e...

Descripción completa

Detalles Bibliográficos
Autores principales: Beyett, Tyler S., To, Ciric, Heppner, David E., Rana, Jaimin K., Schmoker, Anna M., Jang, Jaebong, De Clercq, Dries J. H., Gomez, Gabriel, Scott, David A., Gray, Nathanael S., Jänne, Pasi A., Eck, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085736/
https://www.ncbi.nlm.nih.gov/pubmed/35534503
http://dx.doi.org/10.1038/s41467-022-30258-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085736/
https://www.ncbi.nlm.nih.gov/pubmed/35534503
http://dx.doi.org/10.1038/s41467-022-30258-y

Ejemplares similares